Simplified Refund Resolution
for Covered Entities
The Covered Entity Refund Service (CRS) facilitates the return of ineligible 340B discounts to individual manufacturers. Covered entities work directly with Apexus to efficiently process refunds to manufacturers through a proprietary process, reducing the time and effort spent resolving errors.
CRS brings the expertise of Apexus in 340B compliance, analysis, project management, and reporting to standardize refunds. Covered entities benefit by using CRS to manage their 340B refunds to streamline the process of refund calculation, documentation, and resolution.
340B covered entities must manage the difficult task of returning ineligible 340B discounts to manufacturers accurately and efficiently.
Both covered entities and manufacturers struggle to resolve these errors for a number of reasons:
- Historical drug pricing information is difficult to access for covered entities.
- Manufacturer contacts for refunds are often not publicly available.
- No statutorily defined process governs refunds of ineligible 340B discounts.
- Administering refunds to multiple manufacturers can be a daunting task without appropriate resources.
WHY PARTNER WITH CRS?
We understand the frustrations faced by covered entities and manufacturers when dealing with these issues. Resolving 340B compliance errors is a complex and arduous process, which is why we developed the Covered Entity Refund Service.
Partner with CRS to simplify the refund process and experience a multitude of benefits:
- Accuracy: Our experienced CRS team ensures precise calculations and offers repayments to manufacturers on your behalf.
- Efficiency: Say goodbye to the hours spent searching for manufacturer contacts. We maintain strong relationships with manufacturers to validate appropriate contact information, saving you valuable time, effort, and labor costs.
- Fewer Transactions: Issue only one payment to Apexus. We’ll process and distribute individual payments to each manufacturer on your behalf, and return all remaining amounts at the close of the project.
- Closure: With an average manufacturer response rate of 95% per refund project, CRS reduces the risk of non-responsive manufacturers contacting you later and allows you to stay focused on current work.
- Auditable Records: Rest easy knowing that CRS delivers clear and fully auditable reports, providing transparency and peace of mind.
HOW MUCH DOES CRS COST?
There is no cost to sign up for CRS. Fees are charged during refund projects based on the number of manufacturers contacted. Estimated costs for refunds and CRS fees are provided upfront, ensuring transparency from the start. If multiple labeler codes roll up to one manufacturer, we send one letter and charge the fee only once. Projects are typically completed within two to three months.
Communication and organization were excellent throughout the whole process. We have completed several repayments before internally, and this was by far the best and easiest experience we have had. The process was quick and transparent and saved us hundreds of internal hours spent on the repayments before finding CRS. 
- 340B Program Director in the South
THE APEXUS ADVANTAGE
- CRS maintains a database of manufacturer contacts to eliminate time spent finding the correct contacts for refunds.
- Apexus’ comprehensive list of current and historical WAC prices for 340B NDC codes ensures accurate refund calculations.
- The standardized communication templates, project documentation, and calculation methodology were developed in collaboration with manufacturers, establishing a “best practice” refund offer and approval process.
Curious how the CRS process works?
Click on each step outlined below to learn more.
The Covered Entity Refund Service has successfully refunded over $5 million to more than 200 manufacturers using a consistent process, calculation method best practices, data management, and communication templates.
Are you ready to save time, increase efficiency, and simplify 340B discount refunds?
The Covered Entity Refund Service is a separate Apexus offering that is not a part of the 340B Prime Vendor Program or otherwise associated with the Prime Vendor Agreement between HRSA and Apexus.